The biotechnology company, which is a planned academic spin-off, focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch controlling pathological alterations of the heart following stress or injury. Using a unique approach that modulates entire disease pathways, Cardior Pharmaceuticals aims to address the root causes of cardiac dysfunctions and bring transformative therapeutics and diagnostics to patients. As a leading clinical-stage biopharmaceutical company, Cardior Pharmaceuticals is committed to making a lasting impact on the treatment of cardiac diseases worldwide, which are currently the number one cause of death in the western world.